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175Chapter 8
General discussion and 
future perspectives
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Intestinal fibrosis is a heterogeneous process involving multiple 
complex mechanisms. Despite advances in the understanding of the 
pathophysiology, the incidence of intestinal fibrosis in patients with Crohn’s 
disease (CD) remains high and therapeutic managing of stricturing CD 
remains a challenge in clinical practice.1 Several pharmacologic therapies 
have become available, but none of them have proven to be able to prevent 
or even reverse intestinal fibrosis.2 Surgical resection or strictureplasty are 
currently the only options to treat stenotic intestinal fibrosis.1 
Unravelling the mechanisms of intestinal fibrosis and finding anti-
fibrotic therapies warrants relevant (animal) models. As discussed in the 
introduction of this thesis, several (animal) models for intestinal fibrosis 
are available and the efficacy of therapeutic interventions inhibiting 
formation of fibrosis was proven in some of them.3 To demonstrate the 
efficacy of these anti-fibrotic drugs in patients in a randomized controlled 
trial, well validated end-points for intestinal fibrosis are essential. 
Ideally, this should be serological markers that predict the degree of 
intestinal fibrosis. However, the discovery of markers for intestinal 
fibrosis is difficult since inflammatory and fibrotic pathways partially 
overlap and  concomitant immunomodulatory therapies can obscure 
serological molecular changes related to fibrosis.4 Gaining more insight 
into the pathophysiology of intestinal fibrosis might identify molecular 
(serological) biomarkers for intestinal fibrosis. Discovering a serological 
marker for intestinal fibrosis will have major impact in the management of 
patients with IBD who have fibrotic complications of their disease. In this 
thesis, we aimed to explore new biomarkers, models and mechanisms of 
intestinal fibrosis in Crohn’s disease (CD).
Part I of this thesis aimed at exploring if serological biomarkers for 
formation and degradation of extra-cellular matrix (ECM) can reflect 
intestinal fibrosis formation and degradation (chapter 2), and if these 
markers can predict the response to anti-Tumor Necrosis Factor (TNF) 
therapy in patients with Crohn’s disease (chapter 3 and 4). We tried to 
differentiate between inflammatory, stricturing and penetrating CD based 
on serological biomarkers related to formation and degradation of the 
main interstitial collagens namely collagen type I, type III, type V and 
type VI. Enzymatically cleaved N- and C-terminal pro-peptides of collagen 
quantified by enzyme linked immunosorbent assay (ELISA) were used 
as serological markers of collagen formation. Matrix metalloproteinases 
(MMP) cleaved fragments of degraded collagens quantified by ELISA were 
used as serological markers of collagen degradation. We could differentiate 
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177between penetrating CD versus stricturing and inflammatory CD based on 
an increase in MMP-9 cleaved collagen type III in penetrating ileal CD, 
but increased concentrations of MMP-9 cleaved collagen type III were 
also found in active CD independent of the disease phenotype.5 Because 
penetrating disease is among others driven by inflammation (given the 
fact that anti-inflammatory biologicals are effective in treating fistulising 
CD)6, MMP-cleaved products of collagen type III are also upregulated by 
inflammation and are therefore not effective to differentiate between active 
or penetrating CD. Further research should aim at discovering whether 
other collagen degrading enzymes cleaved degradation markers might be 
specific markers of tissue inflammation in patients with inflammatory 
bowel diseases (IBD) apart from reflecting whether intestinal fibrosis is 
formed or degraded. In that case MMP cleaved fragments of collagens 
could be used to monitor disease activity and to monitor tissue response in 
order to predict the effect of remission-induction therapy in patients with 
active CD as described in chapter 3 and 4 of this thesis.
Unfortunately, the in chapter 2 studied ECM formation and 
degradation markers were not able to differentiate between inflammatory 
and stricturing CD of the terminal ileum (i.e. to distinct fibrosis from 
inflammation), which was the aim of this study and needed to prove the 
efficacy of anti-fibrotic drugs. The generation of MMP degraded fragment 
of collagens is to such an extent dependent on the degree of inflammation 
that the degree of intestinal fibrosis present cannot be monitored using 
these biomarkers.7 Endoscopic or radiological evaluation to determine 
the degree of fibrosis is so far also not possible. A validated endoscopic 
method to classify the degree of fibrosis present is not available and 
endoscopically taken biopsies do not reveal the presence of transmural 
fibrosis as only the mucosa and submucosa can be sampled (which also 
implies that no validated histopathology-based scoring system is available 
to grade the severity of fibrosis).8 Furthermore, studies focussing on 
imaging have shown that the radiologist global impression of whether 
a stricture was ‘active’ or ‘inactive’ was not associated with the presence 
or degree of fibrosis.9,10 Ideally, the level of a (serological) biomarker for 
intestinal fibrosis would not be influenced by the state of inflammation at 
that time. However, such a biomarker is not yet available. Up to now, the 
proposed serologic markers for complicated CD were antibodies against 
microbial antigens (among others antibodies to the outer-membrane porin 
C of Escherichia coli) which are detectable years before diagnosis.11,12 The 
presence of antibodies against microbes in serum in the pre-clinical stage 
of CD might indicate the antecedent loss of intestinal barrier function 
which might precede CD but does not relate to intestinal fibrosis.13–15 Even 
though these factors can predict the risk of complications and surgery, 
these cannot be used to monitor progression to fibro-stenotic disease and 
to monitor response to therapy.11,12 Also genetic risk factors associated 
with a fibro-stenosing phenotype (i.a. a single nucleotide polymorphism 
178(SNP) in the WWOX gene16), cannot be used to monitor progression 
to fibro-stenotic disease as the burden of fibrosis is not reflected in the 
presence or absence of this SNP. Further research focussing on discovering 
serum biomarkers reflecting the degree of intestinal fibrosis present or 
reflecting fibrogenesis to monitor the efficacy of anti-fibrotic drugs, could 
aim at epigenetic (i.a. miR-200b17) markers, at other serologic immune-
assays or at endoscopic molecular imaging. Other potential biomarkers 
for intestinal fibrosis are proteins derived from post-translational 
modifications, which take place outside the cell and can be detected in 
the serum. Post-translational modification of proteins is a non-DNA-
coded change to the composition or structure of a protein that generates 
uniquely modified molecules (proteins) also known as neoepitopes.18 
Post-translational modification occurs enzyme mediated or spontaneous.19 
Measuring neo-epitopes formed by disease specific post-translational 
modifications of a protein (e.g. glycosylation, hydroxylation, citrullination, 
isomerisation) using immune-assays, provides more pathology-relevant 
information compared to measuring the (serum) concentration of the 
protein itself (if at all possible).18 Post-translational formation of collagen 
fibrils is a complex interplay of enzymatic modifications of the collagen 
fibril. As described in chapter 5 of this thesis, mRNA expression of 
several genes involved in post-translational modification of collagens are 
up-regulated in the fibrosis affected area specifically. We observed an 
upregulation in mRNA of the crosslinking enzymes Lysyl-oxidase (LOX, 
including lysyl oxidase like 1-4). Assuming that an increase in mRNA 
expression of these genes leads to an increase in protein expression, the 
enzymatic modifications made by these specific to fibrosis enzymes, may 
create a fibrosis specific profile. Therefore, serum levels of lysyl oxidase 
could reflect the degree of intestinal fibrosis present, as was observed for 
systemic sclerosis, liver fibrosis and atrial fibrosis.20–22 Crosslinking of 
elastin or collagen fibrils by lysyl oxidase is specific for  ECM formation 
and so far has not shown to be regulated by inflammation so far. Further 
research to find serum biomarkers for intestinal fibrosis might be non-
hypothesis driven. An omics (genomics/ transcriptomics/ proteomics/ 
metabolomics) approach on single human blood cells or intestinal 
tissue comparing respectively fibrotic disease/areas to inflammatory 
disease/areas will provide extensive tissue-specific characteristics and 
drug targets.23 Other factors relating to the degree of fibrosis, such as 
post-transcriptional modification (crosslinking) or for example the 
presence of receptors for collagens (see chapter 5, e.g. discoidin domain 
receptor tyrosine kinase 1 or 2, or mannose receptor, C type 2), might 
be endoscopically detectable. By antibody mediated labelling, these 
proteins might be detected and quantified with near-infrared fluorescence 
molecular endoscopy as showed by Nagengast et al. and thereby give 
insight in the degree of fibrosis over inflammation present in an intestinal 
stricture.24 
179Radiological and nuclear imaging could furthermore be considered 
to quantify specifically the degree of intestinal fibrosis. Elastography (a 
non-invasive method to assess the mechanical properties of tissue, in 
particular stiffness), is currently routinely used to quantify renal and liver 
fibrosis.25,26 Elastography is also applicable to the intestine.27 Baumgart et 
al. assessed whether ultrasound based real-time elastography can detect 
gut fibrosis. In a proof of concept study, they found a correlation between 
pre- intra- and post-operative real-time elastography values of unaffected 
and fibrosis affected segments.27,28 Moreover,  a correlation between real-
time elastography values and histologic quantification of intestinal fibrosis 
using Masson trichrome and elastica–van Gieson staining was observed. 
Furthermore as tested in several clinical studies, the degree of active 
IBD can be quantified by more advances techniques such as positron 
emission tomography (PET)/Computed Tomography (CT) or by single-
photon emission computed tomography (SPECT)/CT, as comprehensively 
reviewed by Caobelli et al.29 Whereas 18F- Fludeoxyglucose (FDG)-PET 
can be used to quantify the activity and the extent of the disease as 
it detects metabolism and glycolysis, only 18F- FDG-PET alone is not 
able to differentiate between the fibrotic or inflammatory nature of a 
stricture.29,30 Using SPECT, the degree of fibrosis over inflammation might 
be quantified by anti-body mediated labelling of extra-cellular ECM 
proteins of interest to technetium-99m (99mTc).29 Zhang et al. quantified 
liver fibrosis based on 99mTc-3PRGD2 scintigraphy, which targets integrin 
αvβ3 and thereby assessed the activation of hepatic stellate cells.31 
Activation of intestinal stellate cells is proposed to play a role in intestinal 
fibrosis.32,33 αvβ3 is present in the intestine and detectable using PET.34 
Van den Brande et al. were able to predict the clinical efficacy of the anti-
tumor necrosis factor therapy infliximab by visualizing and quantifying 
intestinal apoptosis by 99mTc–annexin V SPECT.35 They showed that rapid 
anti-TNF-induced apoptosis in the gut predicts the response to anti-TNF 
treatment in patients with active Crohn’s Disease.35 99mTc could be bound 
to antibodies against e.g. extra-cellular collagen itself, to membrane bound 
fibroblast activator protein (FAP) or to (pro-)collagen receptors (see 
above) to confirm and quantify fibrosis (formation). The abovementioned 
imaging modalities that might be suitable to quantify intestinal fibrosis, 
could be used to validate serological biomarkers for intestinal fibrosis, to 
create a well-defined end-point for a clinical trial and to study the effect 
of anti-fibrotic therapies. An intestinal fibrosis specific biomarker (either 
serologic/radiologic/endoscopic) which has sufficient accuracy to be used 
in clinical practice and as end-point for trials evaluating the efficacy of 
anti-fibrotic drugs in human, remains to be discovered but will have a 
major impact on managing fibro-stenotic complications of IBD.8 
Part I of this thesis also describes that serum levels of markers 
for formation and degradation of extracellular matrix turnover, measured 
during the anti-TNF induction phase, can differentiate between clinical 
180responders and non-responders to anti-TNF treatment. The associations 
between response to anti-TNF and differences in concentrations of 
serological markers for collagen formation and degradation, are not 
reflected in concentrations of CRP. As discussed above, serological 
markers which quantify the post-translational modification of a protein, 
can quantify the response of disease affected tissue. The data described in 
chapter 3 is preliminary and should be considered as a proof of concept. 
Before markers can be used in the clinic, validation and determination 
of cut-off values should occur in larger cohorts and for different anti-
inflammatory interventions (e.g. vedolizumab, ustekinumab). Within 
these studies, statistical correction for disease behaviour and e.g. smoking 
behaviour and by imaging quantified length of the affected area or the 
degree of fibrosis present, could be performed. It should be confirmed 
whether concentrations of biomarkers of tissue turnover are e.g. different 
between patients with active colonic Crohn’s disease compared to those 
with active ileal disease, and whether the cut-off values to define the 
response are different between these phenotypes. Furthermore, correlation 
between colonoscopy and faeces calprotectin, currently the most used 
non-invasive marker for gastro-intestinal inflammation, and with MRI-
enterography or perhaps elastography is needed to validate whether serum 
concentrations correlate to tissue response and perhaps to (a reduction in) 
intestinal fibrosis. 
 
181As described above, validated biomarkers for intestinal fibrosis are 
needed to monitor disease progression and to prove the efficacy of anti-
fibrotic drugs. On the other hand, relevant and translationable models for 
intestinal fibrosis are needed to further study disease mechanisms and 
to study the efficacy of anti-fibrotic drugs in the pre-clinical phase. As 
described in the general introduction of this thesis, many comprehensive 
reviews about intestinal fibrosis pathophysiology models have been 
published recently, all stating that further insight into pathways and 
mechanisms is needed.8,36 Models for intestinal fibrosis vary from cell-
culture assays to in vivo mouse models and some of those are translatable 
to the human in vivo environment. This thesis describes a new (more) 
translational model for intestinal fibrosis named precision-cut intestinal 
slices (PCIS, chapter 6). PCIS are prepared from human as well as from 
rat and mouse intestine, which gives the opportunity to compare the effect 
of pro- and anti-fibrotic stimuli in different species. Pharmacological 
effects of the same substance can be different between species.37,38 By 
slicing and incubating PCIS, a spontaneous fibrosis reaction is induced.39 
This effect is also observed in liver, and kidney.40,41 In the study presented 
in chapter 4 of this thesis, human jejunal PCIS were incubated with and 
without stimulation with Tgf-β1. Gene expression of fibrosis markers 
such as collagen type I and α-smooth muscle actin generally decreases 
upon incubation, whereas gene expression of heat shock protein 47 and 
fibronectin increases. Addition of Tgf-β1 induced fibrosis markers in 
mouse and rat PCIS, but not in human PCIS. We concluded that PCIS 
can be used as a model for the early phase of intestinal fibrogenesis in 
the intestine. Differences between mouse/rat and human PCIS observed 
in chapter 4, might be explained by the fact that human PCIS do not 
contain the full cross section of the intestinal and thereby all cells 
present in the intestine. Unfortunately, it is technically not possible to 
prepare human PCIS with a full cross-section of the intestine. This is 
a disadvantage, since especially Crohn’s disease is typically considered 
a transmural disease and since Crohn’s disease associated fibrosis also 
occurs transmural.1 The differences between human PCIS (which only 
contain mucosa and a part of the submucosa) versus mouse and rat 
PCIS (which contain the full thickness of the intestine) in response to 
incubation and pro-fibrotic stimuli, might be explained by the fact that 
cells in the muscularis play a more important role in the process fibrosis 
and stenosis formation in the intestine. Pilot experiments performed 
with PCIS from ileocecal resection due to Crohn’s disease, and from non-
affected ileum and colon obtained from right-sided hemicolectomy due 
to adenocarcinoma of the colon, showed highly variable gene expression 
of fibrosis markers upon incubation (data not shown). Especially fresh 
intestinal tissue from patients with Crohn’s disease was scarce and the 
disease behaviour phenotypes according to the Montreal classification 
was heterogenous. It is questionable if the Montreal classification for CD 
182is discriminant enough to pinpoint different disease mechanisms since 
severity, length of affected bowel and disease progression in time are not 
taken into account in this classification.42–44 Differences in age, disease 
duration, treatment strategies and  microbiome to which these intestines 
were exposed (an element which is certainly disregarded in cell culture 
experiments when antibiotics are added to the culture medium) and in 
the genetic background of these patients causes variation which can be 
expected from translational studies. The use of medication before and at 
time of resection causes high variability in molecular analysis. Ideally, one 
would use tissue from medication naïve patients with Crohn’s disease who 
had an initial resection, but this tissue is even more scarce. The variety of 
different patient related factors, is not the only factor causing variability. 
Data obtained from the PCIS model might be less reproducible because 
the human mucosal/submucosal PCIS vary in the degree of mucosa over 
submucosa due to technical difficulties in dissecting submucosa from 
muscularis, especially in a fibrotic intestine in which the submucosa is 
fibrotic. To further improve the PCIS model as a model for intestinal 
fibrosis, further research should aim at minimizing or stratifying for the 
above-mentioned patient and reducing technical variables as much as 
possible. Furthermore, the morphological and biochemical viability of 
PCIS during incubation should be improved. Incubation time and viability 
might be improved by optimizing cell culture medium (currently used 
is Williams Medium E)39, maybe with the addition of factors needed to 
culture organoids from intestinal stem-cells. This might reduce necrosis 
occurring in PCIS (as shown in the histology figures in chapter 4) and 
making the model more physiological relevant. 
Furthermore, the question arises which factors actually cause 
thickening of the intestinal wall and narrowing of the intestinal lumen 
during intestinal fibrosis. Whether this is predominantly an increase in 
extracellular matrix (ECM) content or as well contraction and stiffening 
of smooth muscle cells in the muscularis and muscularis propria has to 
be determined. ECM remodelling is increasingly recognized a key event 
and an active participant in IBD pathophysiology.45 Intestinal fibrosis 
(in the muscularis) might become self-perpetuating once mechanisms 
of ECM deposition and increased ECM stiffness coincide and augment 
each other.1,46 Tissue stiffness can induce fibrosis formation by activation 
of mesenchymal cells, also in the absence of inflammatory factors.47,48 As 
observed in chapter 5 of this thesis and by others, intestinal stricturing is 
characterized by increased expression of markers for (vimentin-positive) 
mesenchymal cells including myofibroblasts, smooth muscle cells (SMC) 
and fibroblasts; hypertrophy of smooth muscle cells and myofibroblasts; 
and accumulation of excess ECM proteins.49,50  SMC are believed to be 
able to switch from a contractile phenotype to a less mature synthetic 
phenotype. This switch is accompanied by a loss of differentiation with 
decreased expression of contractile markers, increased proliferation as 
183well as the synthesis and the release of several signaling molecules such as 
pro-inflammatory cytokines, chemotaxis-associated molecules, and growth 
factors.51,52 This plasticity of intestinal SMCs and to which extent this leads 
to stricturing of the intestine, could be studied using human PCIS of the 
submucosa/muscularis/serosa. After optimizing and validation of viability 
and morphology of the culture of PCIS, therapeutic interventions on (de)
differentiation of intestinal SMCs and other anti-fibrotic compounds could 
be studied. Ideally, human PCIS would be prepared from human terminal 
ileum and colon as this is where intestinal fibrosis typically occurs.1,53 Most 
likely, intestinal fibrosis occurs in the terminal ileum and colon as this is 
where Crohn’s disease and ulcerative colitis occur. Furthermore, human 
PCIS should be prepared from healthy as well as with Crohn’s disease or 
Ulcerative colitis affected intestine. Comparing human PCIS of disease 
affected terminal ileum with the non-affected proximal resection margin, 
with the affected distal colonic resection margin and with non-IBD 
affected ileum and colon obtained from ileum and colon resection margins 
due to non-inflammatory condition such as adenocarcinoma under further 
improved PCIS incubation conditions, might reveal factors specific for 
intestinal fibrosis that could be used as biomarkers or relevant targets 
for therapy. Further research should also aim at comparing mucosal/
submucosal vs submucosal/muscular/serosal PCIS upon incubation and in 
response to pro-fibrotic stimuli. 
Animal models are needed to obtain further insight into the 
mechanism of intestinal fibrosis. In the pre-clinical phase,  animal models 
are needed to define and understand the pathophysiology of intestinal 
fibrosis.36 Studying animal models for intestinal fibrosis, provide the 
opportunity to perform mechanistic studies (i.e. genetically modified 
animals with a specific knock-out or animals expressing i.e. green-
fluorescent protein ubiquitously to observe cell migration into from a 
transplant recipient into the graft, as was performed in the development 
of the heterotopic transplantation model for intestinal fibrosis)54, as well 
as to test potential anti-fibrotic drugs in the pre-clinical phase. Animal 
models are an indispensable tool to substitute for what cannot be studied 
in humans for ethical, practical and logistic reasons.36 Performing studies 
in animal models enables the investigation of genetically modified 
animals lacking a certain receptor, cytokine or for example lacking the 
ability to initiate V(D)J rearrangement and fail to generate mature T or 
B lymphocytes.36 The model of heterotopic intestinal transplantation 
induced intestinal fibrosis, which is used in chapter 7 of this thesis, is 
one of the available models for intestinal fibrosis. Intestinal fibrosis can 
also be induced in animals (especially in mice) chemically, by bacteria, 
by radiation and by surgery.1 Upon isogenic heterotopic transplantation, 
an ischemic pro-inflammatory response of chronic auto-immune 
mediated rejection is induced, in which rapid onset of fibrosis occurs.54 
Advantages of this model are the rapid onset of fibrosis and the different 
184genotypes that can be examined in the same mouse. A disadvantage is that 
transplanted bowel segments are not perfused and are disconnected from 
the fecal stream. Human anatomy and the physiology of IBD are therefore 
only partially mimicked.1 However, this model does provide a very 
reproducible way to further unravel (new) pathways of intestinal fibrosis 
and to screen therapeutic agents. Mechanisms of fibrosis formation are 
most likely as complex as the mechanisms of intestinal inflammation. As 
hypoxia and inflammation are two sides of the same coin, inflammation 
(leading to transcription of Nuclear factor kappa ß) leads to activation of 
hypoxia pathways (leading to transcription of hypoxia-inducible factor 
(HIF) α and HIF-β) and vice versa.55 An increase in hypoxia in intestinal 
mucosa/submucosa upon or after inflammation causing acidification, 
might perpetuate fibrosis formation by activation of pH-sensing receptors 
and is potentially a new target for therapy.56 pH sensing receptor Ovarian-
G-protein coupled receptor-1 (OGR-1) is not specific to the intestine as 
it is expressed as a single 3.0-kb transcript in several tissues, including 
spleen, testis, small intestine, peripheral blood leukocytes, brain, heart, 
lung, placenta, and kidney.57  Acidification of intestinal tissue might not 
only occur upon inflammation and ischemia, but perhaps as well upon 
acidification due to changes in the intestinal microbiota in a gut with an 
impaired barrier function.14,15 Also smoking might cause acidification of 
tissue and might therefore perpetuate fibrosis formation.58 To which extent 
all above described factors contribute to actual stenosis and symptoms, 
through which (so far undiscovered) receptors and mechanisms stenosis is 
caused and how it can be monitored and reversed, remains an important 
question and should be further studied. Further research should aim 
at exploring the role of the other known pH sensing G-protein coupled 
receptors (GPR4 and T cell death-associated gene 8 (TDAG8)) on 
intestinal fibrosis, and on the effect of targeting OGR1 using an antagonist 
on intestinal fibrosis. 
In conclusion, a serological marker for intestinal fibrosis is not yet 
available, but serological markers of extracellular matrix turnover have 
the potential to reflect intestinal inflammation, intestinal fibrosis and 
to predict response to anti-fibrotic therapy. Moreover, several relevant 
and translational models for intestinal fibrosis to test the anti-fibrotic 
properties of therapies and to study mechanisms are being developed. 
Models for intestinal fibrosis have revealed and will reveal relevant 
mechanisms, biomarkers and drug targets. Biomarkers for intestinal 
fibrosis that predict the effect of anti-inflammatory and anti-fibrotic drugs 
will have major impact on the management and disease course of CD 
patients, especially in patients with a fibrostenotic phenotype. 
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